Inactivation of the p53 tumor suppressor gene is one of the commonest genetic changes identified in human breast cancer. In this review, the structure and function of the p53 gene and its protein products will be discussed, with particular reference to p53 alterations that contribute to carcinogenesis. The frequency and pattern of p53 alterations in breast cancer will be outlined, laboratory methods for their detection briefly summarized, and the potential use of p53 as a prognostic and predictive marker discussed.
1. McBride OW, Merry D, Givol D. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA83:130-134, 1986
2.
2. Miller C, Mohandas T, Wolf D, Prokacimer M, Rotter V, Koeffler PH. Human p53 localized to short arm of chromosome 17. Nature319:783-784, 1986
3.
3. Lamb P, Crawford LV. Characterization of the p53 gene. Mol Cell Biol6:1379-1385, 1986
4.
4. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, Welsh D. The 1993 Walter Hubert lecture: The role of the p53 tumor suppressor gene in tumorigenesis. Br J Cancer69:409-416, 1994
5.
5. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S. Isolation and characterisation of a human p53 cDNA clone: Expression of the human p53 gene. EMBO J3:3257-3262, 1984
6.
6. Soussi T, Caron De Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene5:945-952, 1990
7.
7. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature351:453-456, 1991
8.
8. Nigro JM, Baker S, Preisinger A, Milburn Jessup J, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B. Mutations in the p53 gene occur in diverse tumor types. Nature342:705-708, 1989
9.
9. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancers. Science253:49-53, 1991
10.
10. Soussi T, Caron de Fromental C, Mechali M, May P, Kress M. Cloning and characterisation of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. Oncogene1:71-78, 1987
11.
11. Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J7:855-865, 1993
13. Friend S. p53: A glimpse at the puppet behind the shadow play. Science265:334-335, 1994
14.
14. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science265:346-355, 1994
15.
15. Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth Differentiation2:661-667, 1991
16.
16. Sturzbecher H-W, Maimets T, Chumakov P, Brain R, Addison C, Simanis V, Pudge K, Philp R, Grimaldi M, Court W, Jenkins JR. p53 interacts with p34cdc2 in mammalian cells: Implications for cell cycle control and oncogenesis. Oncogene5:795-801, 1990
17.
17. Stenger J, Mayr G, Mann K, Tegtmeyer P. Formation of stable p53 homotetramers and multiples of tetramers. Mol Carcinogenesis5:102-106, 1992
18.
18. Lee S, Elenbaas B, Levine A, Griffith J. p53 and its 14kDa C-terminal domain recognise primary DNA damage in the form of insertion/deletion mismatches. Cell81:1013-1020, 1995
19.
19. Jayaraman L, Prives C. Activation of p53 sequence specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell81: 1021-1029, 1995
20.
20. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science256:827-829, 1992
21.
21. Fields S, Jang SK. Presence of a potent transcription activating sequence in the p53 protein. Science249:1046-1048, 1990
22.
22. Raycroft L, Wu H, Lozano G. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science249:1049-1051, 1990
23.
23. Vogelstein B, Klinzer KW. p53 function and dysfunction. Cell70:523-526, 1992
24.
24. Otto A, Deppert W. Regulation of mdm-2 expression in meth A tumor cells tolerating wild-type p53. Oncogene8:2591-2603, 1993
25.
25. Farmer GE, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild type p53 activates transcription in vitro. Nature358:83-86, 1992
26.
26. Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann N, Levine AJ, Sheak T. Wild type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A89:12028-12032, 1992
27.
27. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild type p53 can inhibit oncogene mediated focus formation. Proc Natl Acad Sci U S A86:8763-8767, 1989
28.
28. Unger T, Nau MM, Segal S, Minna JD. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J11:1383-1390, 1992
29.
29. Reich NC, Levine AJ. Growth regulation of a cellular tumor antigen, p53, in transformed cells. Nature308:199-201, 1984
30.
30. Donehower LA, Harvey M, Slagle BL, McArthur MT, Montgomery CA, Bulel JS, Bradley A. Mice deficient of p53 are developmentally normal but susceptible to spontaneous tumors. Nature356: 215-221, 1992
31.
31. Martinez J, Georgoff I, Martinez J, Levine AJ. Cellular localization and cell cycle regulation by a temperature sensitive p53 protein. Genes Devel5:151-159, 1991
32.
32. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell62:671-680, 1990
33.
33. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzles KW, Vogelstein B. WAF 1, a potential mediator of p53 tumor suppression. Cell75:1-20, 1993
34.
34. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A89:7491-7495, 1992
35.
35. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage.Cancer Res51:6304-6311, 1991
36.
36. Lane DP, Benchimol S. p53: Oncogene or antioncogene?Genes Devel4:1-8, 1990
37.
37. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature352:345-347, 1991
38.
38. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild type p53 in a human colon tumor derived cell line. Proc Natl Acad Sci U S A89:4495-4499, 1992
39.
39. Lowe SW, Ruley HE, Jacks T, Howsman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell74:957-967, 1993
40.
40. Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild type p53 in pre-B-cell differentiation in vitro. Proc Natl Acad Sci U S A88: 8982-8986, 1991
41.
41. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell71:587-597, 1992
42.
42. Fritsche M, Haessler C, Bradner G. Induction of nuclear accumulation of the tumor suppressor protein p53 by DNA-damaging agents. Oncogene8:307-318, 1993
43.
43. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cipl is a potent inhibitor of GI cyclin-dependent kinases. Cell75:805-816, 1993
44.
44. Lane DP. p53, guardian of the genome. Nature358:15-16, 1992
45.
45. Chen P-L, Chen Y, Bookstein R, Lee W-H. Genetic mechanisms of tumor suppression by the human p53 gene. Science250:1576-1579, 1990
46.
46. Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science240:912-915, 1990
47.
47. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell57:1083-1093, 1989
48.
48. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature362: 847-849, 1993
49.
49. Vogelstein B. A deadly inheritance. Nature348: 681-682, 1990
50.
50. Caron-de-Fromentel C, Soussi T, May P. The p53 protein: From molecular biology to clinical investigations. Med Sci6:352-358, 1990
51.
51. Chang F, Syrjanen S, Tervahauta A, Syrjanen K. Tumorigenesis associated with p53 tumor suppressor gene. Br J Cancer68:653-661, 1993
52.
52. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tiunen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science244: 217-221, 1989
53.
53. Milner J, Metcalf EA, Cook AC. Tumor suppressor p53: Analysis of wild type and mutant p53 complexes. Mol Cell Biol11: 12-19, 1991
54.
54. Milner J, Metcalf EA. Co-translation of activated mutant p53 with wild type drives the wild type into the mutant conformation. Cell65:765-774, 1991
55.
55. Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol63:739-746, 1989
56.
56. Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective mveloid leukemic cells. Cell Growth Diff4:41-47, 1993
57.
57. Hinds PW, Finlay CA, Quartin RS. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: A comparison of the “hot spot” mutant phenotypes. Cell Growth Diff1:571-580, 1990
58.
58. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finkey C, Levine AJ. p53 gain of function mutations. Nature Genetics4:42-46, 1993
59.
59. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A88:10124-10128, 1991
60.
60. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature350:427-428, 1991
61.
61. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature350: 429-431, 1991
62.
62. Li F, Fraumeni JJ. Soft tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome?Ann Intern Med71:747-753, 1969
63.
63. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science250:1233-1238, 1990
64.
64. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li Fraumeni syndrome. Nature348:747-749, 1990
65.
65. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfuss MG, Tucker MA, Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res48:5358-5362, 1988
66.
66. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Morris Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans GR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibez-Koref MF. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li Fraumeni families. Cancer Res54:1298-1304, 1994
67.
67. Malkin D. Germline p53 gene mutations and cancer-Pandora's box or open sesame?JNCI86:326-328, 1994
68.
68. Birch JM, Heighway J, Teare MD, Kelsey AM, Hartley AC, Tricker KJ, Crowther D, Lane DP, Santibez-Koref MF. Linkage studies in a Li Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer70:1176-1181, 1994
69.
69. lavarone A, Matthay KK, Steinkirchner TM, Israel MA. Germline and somatic p53 gene mutations in multifocal osteogenic sarcoma. Proc Natl Acad Sci U S A89:4207-4209, 1992
70.
70. Malkin D, Jolly KW, Barbier N, Look T, Friend SH, Gebhardt MC, Andersen TI, Borrensen A-L, Frederick P, Gurber J, Strong LC. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med326:1309-1315, 1992
71.
71. Barnes DM, Hanby AM, Gillett CE, Mohammed S, Hodgson S, Bobrow LG, Leigh IM, Purkis T, Mac-Geogh C, Spurr NK, Bartek J, Vojtesek B, Picksley SM, Lane DP. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet340:259-263, 1992
72.
72. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40 transformed cells. Nature278:261-263, 1979
73.
73. Linzer DIH, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell17:43-52, 1979
74.
74. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degeneration of p53. Cell63:1129-1136, 1990
75.
75. Fakharzadeh SS, Rosenblum-Vos L, Murphy M, Hoffman EK, George DL. Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. Genomics15: 283-290, 1993
76.
76. Finlay CA. The mdm-2 oncogene can overcome wild type p53 suppression of transformed cell growth. Mol Cell Biol13:301-306, 1993
77.
77. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell69:1237-1245, 1992
78.
78. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature358:80-86, 1992
79.
79. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature362:857-860, 1993
80.
80. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res53:2231-2234, 1993
81.
81. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res53:16-18, 1993
82.
82. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res53:2736-2739, 1993
83.
83. McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, Dervan PA. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer71:981-985, 1995
84.
84. Brambilla E, Gazzeri S, Moro D, Caron de fromentel C, Gouyer V, Jacrot M, Brambilla C. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol143:199-210, 1993
85.
85. Moll UM, Riou G, Levine AJ. TWo distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion. Proc Natl Acad Sci U S A89:7262-7266, 1992
86.
86. Gannon JV, Lane DP. Protein synthesis required to anchor a mutant p53 protein which is temperature sensitive for transport. Nature349:802-806, 1990
87.
87. Takahashi K, Suzuki K. DNA synthesis-associated nuclear exclusion of p53 in normal human breast epithelial cells in culture. Oncogene9:183-188, 1994
88.
88. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer30:403-408, 1982
89.
89. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, Caron De Fromentel C, Preudhomme C, Fenaux P, Fournier G, Mangen P, Laurent Puig P, Pelletier G, Schlemberger M, Desgrandchamps F, Le DC, Peyrat JP, Janin N, Bressac B, Soussi T. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution of primary structure and exposure of protein surface. Cancer Res53:5872-5876, 1993
90.
90. Vojtesek B, Fisher CJ, Barnes DM, Lane DP. Comparison between p53 staining in tissue sections and p53 protein levels measured by an ELISA technique. Br J Cancer67:1254-1258, 1993
91.
91. Green JA, Mudenda B, Tarunina M, Jenkins JJ, Leinster SJ. Serum autoantibody to p53 in breast cancer patients: Relationship to tumor differentiation. Proc Annu Meet Am Assoc (Cancer Res33:2223-2223, 1992
92.
92. Hassapoglidou S, Diamandis EP. Antibodies to the p53 tumor suppressor gene product quantified in cancer patient serum with a time-resolved immunofluorometric technique. Clin Biochem25:445-449, 1992
93.
93. Borg A, Lennerstrand J, Stenmark-Askmalm M, Ferno M, Brisfors A, Ohruik A, Stal O, Killander D, Lane D, Brundell J. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer71:1013-1017, 1995
94.
94. Levesque MA, Diamandis EP, Yu H, Sutherland DJA. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Res Treat30: 179-195, 1994
96. Orita M, Iwahana H, IKanazanra H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single strand conformational polymorphisms. Proc Natl Acad Sci U S A86:2766-2770, 1989
97.
97. Myers RM, Fischer SG, Lerman LS, Maniatis T. Detection and localisation of single base changes by denaturing gel electropheresis. Methods Enzymol155:501-527, 1987
98.
98. Andersen TI, Borresen A. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas: Advantages of using constant denaturant gel electrophoresis in mutation detection. Diagn Mol Pathol4:203-211, 1995
99.
99. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J. p53 mutations in breast cancer. Cancer Res52:5291-5298, 1992
100.
100. Iggo R, Gatter K, Bartek J, Lane D, Harris A. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet335:675-679, 1990
101.
101. Thor AD, Yandell DW. Prognostic significance of p53 overexpression in node-negative breast carcinoma: Preliminary studies support cautious optimism. JNCI85:176-177, 1993
102.
102. Fisher CJ, Gillet CE, Vojtesek B, Barnes DM, Millis RR. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer69:26-31, 1994
103.
103. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane DP, Barnes DM. Analysis of p53 expression in human tumors: An antibody raised against human p53 expressed in E. coli. J Cell Sci101:183-189, 1992
104.
104. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunohistochemical analysis of the human nuclear phosphoprotein p53: New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Meth151:237-244, 1992
105.
105. Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol169:27-34, 1993
106.
106. Legros Y, Lacabanne V, D'Agay MF, Larsen CJ, Pla M, Soussi T. Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull Cancer80:102-110, 1993
107.
107. Kerns B-J, P.A. J, Moore M-B. p53 overexpression in formalin-fixed, paraffin embedded tissue detected by immunohistochemistry. J Histochem Cytochem40:1047-1051, 1992
108.
108. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene5:893-899, 1990
109.
109. Charpin C, DeVictor B, Andrac L, Amabile J, Bergeret D, LaVaut M-N, Allasia C, Piana L. p53 quantitative immunocytochemical analysis in breast carcinomas. Hum Pathol26:159-166, 1995
110.
110. Gannon JV, Hinds PW, Tan H, Eliyahu D, Oren M, Levine AJ. Activating mutations in p53 produce a common conformational effect: A monoclonal antibody specific for the mutant form. EMBO J9:1595-1602, 1990
111.
111. Wynford-Thomas D. p53 in tumor pathology: Can we trust immunocytochemistry?J Pathol166:329-330, 1992
112.
112. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams IKE, House AK, lacopetta BJ. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol (in press)
113.
113. Hall PA, McKee PH, Menage HdP, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene8:203-207, 1993
114.
114. Hall PA, Lane DP. p53 in tumor pathology: Can we trust immunohistochemistry?-revisited!J Pathol172:1-4, 1994
115.
115. Bodner SM, Minna JD, Jensen SM. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene7:743-749, 1992
116.
116. Battifora H. p53 Immunohistochemistry: A word of caution. Hum Pathol25:435-436, 1994
117.
117. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis?Hum Pathol24:469-476, 1993
118.
118. Silvestrini R, Benini E, Daidone MG, Veneroni S, Borrachi P, Cappalletti V, Di Fronzo G, Veronesi U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. JNCI85:965-970, 1993
119.
119. Baas IO, Mulder JWR, Offerhaus JA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol172:5-12, 1994
120.
120. Dix BR, Robbins PD, Soong R, Jenner D, House AK, lacopetta BJ, and the General Surgeons at Sir Charles Gairdner Hospital. The common molecular genetic alterations in Dukes' B and Dukes' C colorectal carcinoma are not short term prognostic indicators of survival. Int J Cancer59:747-751, 1994
121.
121. Dix B, Robbins P, Carrello S, House A, Iacopetta B. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. Br J Cancer70:585-590, 1994
122.
122. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed paraffin embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem39:741-748, 1991
123.
123. Van den Berg FM, Bacs IO, Polak MM, Offerhaus GA. Detection of p53 overexpression in routinely paraffin embedded tissue of human carcinomas using a novel target unmasking fluid. Am J Pathol142:381-385, 1993
124.
124. Prosser J, Elder PA, Condie A, MacFadyen I, Steel CM, Evans HJ. Mutations in p53 do not account for heritable breast cancer: A study in five affected families. Br J Cancer63:181-184, 1991
125.
125. Warren W, Eeles RA, Ponder BAJ, Easton DF, Averill D, Ponder MA, Anderson K, Evans AM, DeMars R, Love R, Dundas S, Stratton MR, Trowbridge P, Cooper CS, Peto J. No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. Oncogene7:1043-1046, 1992
126.
126. Preudhomme C, Fenaux P, Peyrat JP, Fournier J, Bonneterre J, Vennin P. Absence of germline mutations of exons 5 to 8 of the p53 gene in 26 breast cancer families from the north of France. Eur J Cancer10:1476-1478, 1993
127.
127. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Sheltpon B, Prestigiacomo L, Vogelstein B, Davidson N. Inherited p53 gene mutations in breast cancer. Cancer Res52:2984-2986, 1992
128.
128. Borresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjord J, Ottestad L, Smith-Sorrenson B, Hovig E, Malkin D, Friend SH. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res52:3234-3236, 1992
129.
129. Lidereau R, Soussi T. Absence of p53 germ-line mutations in bilateral breast cancer patients. Hum Genet89:250-252, 1992
130.
130. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Hagen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristo PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhaussen S, Cannon Albright L, Goldger D, Wiuseman R, Kanb A, Skolnick MH. A strong candidate for the breast and ovarian cancer susceptibility Gene BRCA1. Science266:66-71, 1994
131.
131. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCAI-mutation carriers. Lancet343:692-695, 1994
132.
132. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen S, Seal S, Tran T, Averill D, Fields P, Marshall G, Narod S, Lenoir GM, Lynch H, Feunten J, Devilee P, Cornelisse CJ, Menko FH, Daly PA, Ormiston W, McManus R, Pye C, Lewis CM, Cannon Albright LA, Peto J, Ponder BAJ, Skolnick MH, Easton DF, Goldger DE, Stratton MR. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q 12-13. Science265:2088-2090, 1994
133.
133. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Bigs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A, Stratton MR. Identification of the breast cancer susceptibility gene BRCA2. Nature378:789-792, 1995
134.
134. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc J-F, Mitchell JT, McArthur Morrison J, Nguyen K, Peng Y, Samson S, Schroeder M, Snyder SC, Steel L, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A, Tran T, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AKC, Shizuya H, Eyfjord JE, Cannon-Albright L, Labrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genetics12:333-337, 1996
135.
135. Callahan R, Cropp CS, Merlo GR, Liscia DS, Cappa APM, Lidereau R. Somatic mutations and human breast cancer. Cancer (Suppl)69:1582-1588, 1992
136.
136. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, Kakamura Y. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res50:7184-7189, 1990
137.
137. Thompson AM, Anderson TJ, Condie A. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer50:528-532, 1992
138.
138. Andersen TI, Gaustad A, Ottestad L. Genetic alterations of the tumor suppressor gene regions 3p, lip, 13q, 17p, and 17q in human breast carcinomas. Genes Chromosom Cancer4:1992
139.
139. Singh S, Simon M, Meybohm I, Jantke I, Jonat W, Maass H, Goedde HW. Human breast cancer: Frequent p53 allele loss and protein overexpression. Hum Genet90:635-640, 1993
140.
140. Lindblom A, Skoog L, Andersen TI, Rotstein S, Nordenskjold M, Larrson C. Four separate regions on chromosome 17 show loss of heterozygosity in familial breast carcinomas. Hum Genet91:6-12, 1993
141.
141. Thorlacius S, Jonasdottir O, Eyfjord J. Loss of heterozygosity at selective sites on chromosomes 13 and 17 in human breast carcinoma. Anticancer Res11:1501-1508, 1991
142.
142. Borresen A-L, Hovig E, Smith-Sorensen D, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A88:8405-8409, 1991
143.
143. Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa APM, Chiba T, Takahashi T, Nau MM, Callahan R, Minna JD. Mutations in the p53 gene in primary human breast cancers. Cancer Res51:6194-6198, 1991
144.
144. Deng G, Chen L-C, Schott DR, Thor A, Bhargava V, Ljung B-M, Chew K, Smith HS. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Res54:499-505, 1994
145.
145. Thompson AM, Steel CM, Chetty U, Hawkins RA, Miller WR, Carter DC, Forrest APM, Evans HJ. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer61:74-78, 1990
146.
146. Chen LC, Neubauer A, Kurisu W, Waldman FM, Ljung BM, Goodson W, Goldman ES, Moore D, Balazs M, Liu E, Mayall BH, Smith HS. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci U S A88:3847-3851, 1991
147.
147. Kovach JS, McGovern RM, Cassady JD, Swanson A, Wold LE, Vogelstein B, Sommers S. Direct sequencing from touch preparations of human carcinomas: Analysis of p53 mutations in breast carcinomas. JNCI83:1004-1009, 1991
148.
148. Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S. Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci U S A88:10657-10661, 1991
149.
149. Devilee P, Pearson PL, Cornelisse CJ. Allele losses in breast cancer. Lancet1:154-154, 1989
150.
150. Jacquemier J, Moles JP, Penault-Llorca F, Adelaide J, Torrente M, Viens P, Birnbaum D, Theillet C. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: Comparison of staining and PCR-SSCP results. Br J Cancer69:846-852, 1994
151.
151. Thorlacius S, Borresen A-L, Eyfjord JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: A prognostic factor. Cancer Res53:1637-1641, 1993
152.
152. Merlo GR, Bernard A, Diella F, Venesio T, Cappa APM, Callahan R, Liscia DS. In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S-phase index. Int J Cancer54:531-535, 1993
153.
153. Faille A, De-Cremoux P, Extra JM, Linares G, Espie M, Barstyn E, DeRocquancourt A, Giachetti S, Marty M, Calvo F. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer69:1145-1150, 1994
154.
154. Prosser J, Thompson AM, Granston G, Evans HJ. Evidence that p53 behaves as a tumor suppressor gene in sporadic breast tumors. Oncogene5:1573-1579, 1990
155.
155. Varley JM, Brammar WJ, Lane DP, Swallow JE, Dolan C, Walker RA. Loss of chromosome 17pl3 sequences and mutation of p53 in human breast carcinomas. Oncogene6:413-421, 1991
156.
156. Mazars R, Spinardi L, BenChiek M, Simony-La-fontaine J, Jeanteur P, Theillet C. p53 mutations occur in aggressive breast cancer. Cancer Res52:3918-3923, 1992
157.
157. Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchitti D, Callahan R, Bistocchi M. p53 mutations and histological type of invasive breast cancer. Cancer Res53:4665-4669, 1993
158.
158. Biggs PJ, Warren W, Venitt S, Stratton MR. Does a genotoxic carcinogen contribute to human breast cancer? The value of mutational spectra in unravelling the aetiology of cancer. Mutagenesis8:275-283, 1993
159.
159. Blaszyk H, Vaughn CB, Hartmann A, McGovern R, Schroeder JJ, Cunningham J, Schaid D, Sommer SS, Kovach JS. Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer. Lancet343:1195-1197, 1994
160.
160. Tsuda H, Hirohashi S. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer57:498-503, 1994
161.
161. Caleffi M, Teague MW, Jensen RA, Vnenack-Jones CL, Dupont WD, Parl FF. p53 gene mutations and steroid receptor status in breast cancer. Cancer73:2147-2156, 1994
162.
162. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL. Prognostic significance of TP53 alterations in breast cancer. Br J Cancer68:540-548, 1993
163.
163. Sasa M, Kondo K, Komaki K, Uyama T, Morimoto M, Monden Y. Frequency of spontaneous p53 mutations (CpG site) in breast cancer in Japan. Breast Cancer Res Treat27:247-252, 1993
164.
164. Sasa M, Kondo K, Komaki K, Morimoto T, Monden Y. p53 alteration correlates with negative ER, negative PGR, and high histologic grade in breast cancer. J Surg Oncol56:46-50, 1994
165.
165. Elledge RM, Fuqua SAW, Clark GM, Pujol P, Allred DC. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treat27:95-102, 1993
166.
166. Dunn JM, Hastrich DJ, Armstrong JS, Davies JD, Maitland NJ, Farndon JR. The detection of p53 mutations in human breast cancer using PCR-SSCP (meeting abstract). J Pathol167:143A-143A, 1992
167.
167. Sommer SS, Cunningham J, McGovern RN, Saitoh S, Schroeder JJ, Wold LE, Kovach JS. Pattern of p53 gene mutations in breast cancers of women of the midwestern United States. JNCI84:246-252, 1992
168.
168. Lohmann D, Ruhri C, Schrnitt M, Graeff H, Hofler H. Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer. Diagn Mol Pathol2:36-41, 1993
169.
169. Bergh J, Norberg T, Sjorgren S, Lindgren A, Holm-berg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Medicine1:1029-1034, 1995
170.
170. Shiao Y, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res55:1485-1490, 1995
171.
171. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reishaus E, Lynch HT, Marcus JN, Schwartz L, Chen L-C, Mayall BH, Smith HS. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancer. JNCI84:845-855, 1992
172.
172. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A88:5006-5010, 1991
173.
173. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. JNCI85:200-209, 1993
174.
174. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, Lennard TJW, Angus B, Horne CHW. p53 expression in human breast cancer related to survival and prognostic factors: An immunohistochemical study. J Pathol164:75-81, 1991
175.
175. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Murai K, Hirohashi S. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Japanese J Cancer Res82:835-840, 1991
176.
176. Horak E, Smith K, Bromley L, LeJeune S, Greenall M, Lane D, Harris AL. Mutant p53, EGF receptor and c-erb B-2 expression in human breast cancer. Oncogene6:2877-2884, 1991
177.
177. Davidoff AM, Herndon JE, Glover NS, Kerns B-JM, Pence JC, Iglehart JD, Marks JR. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery110:259-264, 1991
178.
178. Poller DN, Hutchings CE, Galea M, Bell JA, Nicholson RA, Elston CW, Blamey RW, Ellis IO. p53 protein expression in human breast cancer: relationship to expression of epidermal growth factor receptor, c-erb B-2 protein overexpression, and oestrogen receptor. Br J Cancer66:583-588, 1992
179.
179. Walker RA, Dearing SJ, Lane DP, Varley JM. Expression of p53 protein in infiltrating and insitu breast carcinomas. J Pathol165:203-211, 1991
180.
180. Domagala W, Harezga B, Szadowska A, Markiewski M, Weber K, Osborn M. Nuclear p53 protein accumulates preferentially in medullary and highgrade ductal but rarely in lobular breast carcinomas. Am J Pathol142:669-674, 1993
181.
181. Bosari S, Lee AKC, Viale G, Heatley GJ, Coggi G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch A421:291-295, 1992
182.
182. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. p53 expression in breast cancer. Int J Cancer41:178-183, 1988
183.
183. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD. p53 and c-erb B-2 protein expression in breast carcinomas. Am J Clin Pathol98:408-418, 1992
184.
184. Sawan A, Randall B, Angus B, Wright C, Henry JA, Ostrowski, J, Hennessy C, Lennard TWJ, Corbett I, Horne CHW. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immuohistochemical study. J Pathol168:23-28, 1992
185.
185. Spandidos DA, Karaiossifidi H, Malliri A, Linardopoulos S, Vassilaros S, Tsikkinis A, Field JK. Expression of Ras, Rbl and p53 proteins in human breast cancer. Anticancer Res12:81-90, 1992
186.
186. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: An immunohistological study of epidemiological risk factors, histological features and prognosis. J Clin Oncol13:821-830, 1995
187.
187. Haerslev T, Jacobsen GK. An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen and prognosis. Hum Pathol26:295-301, 1995
188.
188. Beck T, Weller EE, Weikel W, Brumm C, Wilkens C, Knapstein PG. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: Correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol57:96-104, 1995
189.
189. Elledge RM, Clark GM, Fuqua SAW, Yu Y, Allred CA. p53 protein accumulation detected by five different antibodies: Relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res54:3752-3757, 1994
190.
190. Hurlimann J. Prognostic value of p53 protein expression in breast carcinomas. Pathol Res Pract189:996-1003, 1993
191.
191. Marks JR, Humphrey PA, Wu K, Berry D, Banderenko N, Kerns B-JM, Iglehart JD. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg219:332-341, 1994
192.
192. Stenmark-Askmalm M, Stal O, Sullivan S. Cellular accumulation of p53 protein: An independent prognostic factor in stage II breast cancer. Eur J Cancer30:175-180, 1994
193.
193. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erb B-2 protein. Hum Pathol24:463-468, 1993
194.
194. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer72:3641-3647, 1993
195.
195. Soini Y, Vahakangas K, Nuorva K, Kamel D, Lane DP, Paako P. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumors. J Pathol168:29-33, 1992
196.
196. Bartkova J, Bartek J, Vojtesek B, Lukas J, Rejthar A, Kovarik J, Milliss RR, Lane DP, Barnes DM. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumors. Eur J Cancer29:881-886, 1993
197.
197. Lipponen P, Aaltomaa HJS, Syrjanen S, Syrjanen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer55:51-56, 1993
198.
198. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S. Relationship between p53 expression and other prognostic factors in human breast carcinoma: An immunohistochemical study. Am J Clin Pathol100:213-217, 1993
199.
199. Trudel M, Mulligan L, Cavenee W, Margolese R, Cote J, Gariepy G. Retinoblastoma and p53 gene product expression in breast carcinoma: Immunohistochemical analysis and clinicopathologic correlation. Hum Pathol23:1388-1394, 1992
200.
200. Isola J, Visakorpi T, Holli K, Kallioniemi O-P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. JNCI84:1109-1114, 1992
201.
201. Hanzal E, Gitsch G, Kohlberger P, Dadak CH, Miechowiecka N, Breitenecker G. Immunohistochemical detection of mutant p53-suppressor gene product in patients with breast cancer: Influence on metastasis-free survival. Anticancer Res12:2325-2330, 1992
202.
202. Drobnjak M, Cote RJ, Saad AD, Drudis T, Fuks Z, Cordon-Cardo C. p53 and Rb alterations in primary breast cancer: correlation with hormone receptor expression and lymph node metastases. Int J Oncol2:173-178, 1993
203.
203. Daidone MG, Benini E, Veneroni S, Di-Fronzo G, Silvestrini R. p53 expression is an independent prognostic marker in node-negative breast cancer (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol12:A30-A30, 1993
204.
204. Gasparini G, Bevilacqua P, Boracchi P, Maluta S, Dalla Palma P, Caffo O, Barabareschi M, Borrachi P, Marubini E, Pozza F. Prognostic value of p53 expression in early-stage breast carcinoma compared with tumor angiogenesis, epidermal growth factor receptor, c-erbB-2, cathepsin D, DNA ploidy, parameters of cell kinetics and conventional features. Int J Oncol4:155-162, 1994
205.
205. O'Malley FP, Vnencak-Jones CL, Dupont WD, Parl F, Manning S, Page DL. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab Invest71:67-72, 1994
206.
206. Humphrey PA, Franquemont DW, Geary WA, Kerns B-J, Iglehart JD, Marks JR. Immunodetection of p53 protein in non-invasive epithelial proliferative breast disease. Appl Immunohistochem2:22-28, 1994
207.
207. Heyderman E, Dagg B. p53 immunostaining in benign breast disease. Lancet338:1532-1532,1991
208.
208. Younes M, Lebovitz RM, Bommer KE. p53 accumulation in benign breast biopsy specimens. Hum Pathol155-158, 1995
209.
209. Micelli G, Donadeo A, Quaranta M. The p53 tumor suppressor gene. A preliminary clinical study in breast cancer patients. Cell Biophys21:25-31, 1992
210.
210. Marsigliante S, Leo G, Mottaghi A, Biscozzo L, Greco S, Storelli C. p53 associated with cathepsin D in primary breast cancer. Int J Clin Lab Res23: 102-108, 1993
211.
211. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Terunina M, Leinster SJ. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer69: 1115-1119,1994
212.
212. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A89:3439-3442, 1992
213.
213. Lipton J, Leizel K, Carney W, Lowder J, Chinchilli V, Demers L, Harry H, Lipton A. Elevated mutant p53 levels in breast cancer cytosols (Meeting abstract)Proc Annu Meet Am Assoc Cancer Res34A:1163-1163, 1993
214.
214. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res52:4168-4174, 1992
215.
215. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res52:6380-6384, 1992
216.
216. Bennett WP, Hollstein MC, Metcalf RA. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res52:6092-6097, 1992
217.
217. Sozzi G, Miozzo M, Doghi R. Deletions of 17p and p53 mutations in preneoplastic lesions ofthe lung. Cancer Res52:6079-6082, 1992
218.
218. Nakanishi Y, Noguchi M, Matsuno M, Mukai K, Shimosato Y, Hirohashi S. p53 expression in squamous cell carcinoma and dysplasia of the vocal cords and oral cavity. Appl Immunohistochem1:101-107, 1993
219.
219. Hayashi Y, Yamashita J, Yamaguchi K. Timing and role of p53 gene mutation in the recurrence of glioma. Biochem Biophys Res Communications180:1145-1150, 1991
220.
220. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature355:846-847, 1992
221.
221. Davidoff AM, Kerns B-JM, Iglehart JD, Marks JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res51:2605-2610, 1991
222.
222. Leal CB, Schmitt FC, Bento MJ, Maia NC, Lopes CS. Ductal carcinoma in situ of the breast. Histological characterisation and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53 and c-erbB-2 protein. Cancer75:2123-2131, 1995
223.
223. O'Malley FP, C.L. V-J, Dupont WD, Parl F, Manning S, Page DL. p53 mutations in ductal carcinoma in situ of the breast: Immunohistochemical and sequencing data [abstract] Mod Pathol6:18A-18A, 1993
224.
224. Thompson AM. p53 and breast cancer. The Breast2:8-10, 1993
225.
225. Elledge RM, McGuire WL, Osborne CK. Prognostic factors in breast cancer. Semin Oncol19:244-253, 1992
226.
226. Page DL. Prognosis and breast cancer: Recognition of lethal and favorable prognostic types. Am J Surg Pathol15:334-349, 1991
227.
227. Clark GM. Do we really need prognostic factors for breast cancer?Breast Cancer Res Treat30:117-126, 1994
228.
228. Tsuda H, Iwaya K, Fukutomi T, Hirohashi S. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histological grade. Jpn J Cancer Res84:394-401, 1993
229.
229. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, Coindre J-M. Prognostic value of p53 in breast invasive ductal carcinoma: An immunohistochemical study on 942 cases. Breast Cancer Res Treat36:71-81, 1995
230.
230. Soini Y, Paakko P, Nuorva K, Kamel D, Lane DP, Vahakangas K. Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Arch A421:223-228, 1992
231.
231. Merlo GR, Venesio T, Taverna D, Marte BM, Callahan R, Hynes NE. Growth suppression of normal mammary epithelial cells by wild-type p53. Oncogene9:443-453, 1994
232.
232. Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JRC, Meli S, Boracchi P, Testolin A, La Malfa G, Pozza F. Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol10:686-695, 1992
233.
233. Riou G, Le MG, Travagli JP, Levine AJ, Moll UM. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast cancer. JNCI85:1765-1767, 1993
234.
234. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Borracchi P, Testolin A, Pozz F, Folkman J. Tumor microvessel density, p53 expression, tumor size and peritumoral lymph vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol12:454-462, 1994
235.
235. Callahan R. p53 mutations, another breast cancer prognostic factor. JNCI84:826-827, 1992
236.
236. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat32:39-47, 1994
237.
237. McGuire WL. Breast cancer prognostic factors: Evaluation guidelines. JNCI83:154-155, 1991
238.
238. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. JNCI85:1206-1219, 1993
240. Bosari S, Viale G. The clinical significance of p53 aberrations in human tumors.Virchows Arch A427:229-241, 1995
241.
241. Lowe SW. p53 status and the efficacy of cancer therapy. Science266:807-810, 1994
242.
242. Clark AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent pathways. Nature362:849-852, 1993
243.
243. Jacquemier J, Penault-Llorca F, Viens P, Houvenaeghel G, Hassoun J, Torrente M, Adelaide J, Birnbaum F. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res14:2773-2778, 1994
244.
244. Koechli OR, Schaer GN, Seifert B. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet344:1647-1648, 1994
245.
245. Mathieu MC, Koscielny S, Le Bihan ML, Spielmann M, Arriagada R. p53 protein overexpression and chemosensitivity in breast cancer. Lancet345:1182-1182, 1995
246.
246. Makris A, Powles TJ, Dowsett M, Allred C. p53 protein overexpression and chemosensitivity in breast cancer. Lancet345:1181-1182, 1995
247.
247. Elledge RM, Gray R, Mansour E, Yu Y, Clark GM, Ravdin P, Osborne CK, Gilchrist K, Davidson NE, Robert N, Tormey DC, Allred DC. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. JNCI87:1254-1256, 1995
248.
248. Moll UM, Osterrneyer AG, Ahomadeegbe J, Mathieu M, Riou G. p53 mediated tumor cell response to chemotherapeutic DNA damage: A preliminary study in matched pairs of breast cancer biopsies. Hum Pathol26:1293-1301, 1995
249.
249. Rogan E, Reddel R. p53: The key to cancer?Today's Life Science August:24-35, 1993
